Can a person taking methotrexate (methotrexate) for an existing medical condition take attention deficit hyperactivity disorder (ADHD) medication, such as methylphenidate (methylphenidate), amphetamine (amphetamine), or atomoxetine (atomoxetine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can a Person Taking Methotrexate Take ADHD Medication?

Yes, a person taking methotrexate can safely take ADHD medications including methylphenidate, amphetamines, and atomoxetine, as there are no known clinically significant drug interactions between methotrexate and standard ADHD medications.

No Contraindication Exists

  • There is no documented contraindication to combining methotrexate with ADHD medications in current clinical practice guidelines 1.
  • The 2002 American Academy of Child and Adolescent Psychiatry practice parameters for stimulant medications list specific contraindications including MAO inhibitors, psychosis, glaucoma, liver disorders (for pemoline only), and active stimulant abuse, but methotrexate is not mentioned 1.
  • While methotrexate guidelines note that "comorbidities or drug interactions that may exacerbate toxicity make this intervention inappropriate for select patients," this refers to interactions that affect methotrexate toxicity itself, not ADHD medications 2.

ADHD Medication Options

Stimulant medications (first-line treatment):

  • Methylphenidate and amphetamine-based stimulants work for 70-80% of people with ADHD and are typically the first choice 3, 4.
  • These medications have no known pharmacokinetic or pharmacodynamic interactions with methotrexate 4, 5.

Non-stimulant alternatives (if stimulants are not tolerated or preferred):

  • Atomoxetine is a selective norepinephrine reuptake inhibitor that can be used as monotherapy, with a target dose of 60-100 mg daily for adults 6, 7.
  • Atomoxetine requires 6-12 weeks to achieve full therapeutic effect and is particularly useful when there are concerns about stimulant use 6, 8.
  • Other non-stimulant options include guanfacine, clonidine, bupropion, and viloxazine 3, 4.

Important Monitoring Considerations

For methotrexate patients specifically:

  • Continue routine methotrexate monitoring (liver function tests, complete blood counts) as prescribed, regardless of ADHD medication use 2.
  • The only ADHD medication with liver-related concerns is pemoline (no longer commonly used), which should not be used in patients with preexisting liver disease 1.

For ADHD medications:

  • Monitor blood pressure and pulse regularly with stimulants, as they cause statistically significant increases 6.
  • With atomoxetine, monitor for suicidal ideation, clinical worsening, and unusual behavioral changes, especially during initial months or dose changes 6, 7.

Clinical Approach

Start with stimulants unless contraindicated:

  • Methylphenidate or amphetamine-based medications are recommended as first-line treatment due to superior efficacy 3, 4, 5.
  • The presence of methotrexate therapy does not change this recommendation.

Consider atomoxetine if:

  • Patient has concerns about controlled substances 7, 8.
  • Patient has comorbid anxiety or tics 7.
  • Patient has history of substance use disorders 6, 7.

Common pitfall to avoid:

  • Do not unnecessarily withhold effective ADHD treatment due to unfounded concerns about methotrexate interactions. The risks of untreated ADHD (impaired functioning, accidents, poor quality of life) outweigh theoretical concerns when no documented interaction exists 4, 8.

References

Guideline

practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults.

Journal of the American Academy of Child and Adolescent Psychiatry, 2002

Guideline

attention-deficit/hyperactivity disorder in pregnancy and the postpartum period.

American Journal of Obstetrics and Gynecology, 2024

Research

Current Pharmacological Treatments for ADHD.

Current topics in behavioral neurosciences, 2022

Research

Current pharmacotherapy of attention deficit hyperactivity disorder.

Drugs of today (Barcelona, Spain : 1998), 2013

Guideline

Treatment of Methamphetamine Use Disorder with Comorbid ADHD

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

A critical appraisal of atomoxetine in the management of ADHD.

Therapeutics and clinical risk management, 2016

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.